What You Need To Know About Jaguar Health Inc. (JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) trading with an addition of $0.11 to $2.08 on Thursday, an upside of 5.69 percent. An average of 1,032,794 shares of common stock have been traded in the last five days. There was a fall of -$0.2108 in the past week. The last 20 days have seen an average of 1,574,474 shares traded, while the 50-day average volume stands at 1,439,054.

JAGX stock has decreased by -31.60% in the last month. The company shares reached their 1-month lowest point of $1.9121 on 10/07/21. With the stock rallying to its 52-week high on 01/08/21, shares of the company touched a low of $0.56 and a high of $13.41 in 52 weeks. In spite of this, the price is down -84.47% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

125 days have passed since Jaguar Health Inc. (JAGX) last reported insider trading activity. BOCHNOWSKI JAMES J, who is Director, most recently acquired $152 shares at $1.74 per share on Jun 04. In this transaction, the insider spent $264. Director, BOCHNOWSKI JAMES J, disposed of 292 shares at a price of $1.75 on Jun 03. The insider now owns more than $511 worth of shares.

Valuation Metrics

Jaguar Health Inc. (JAGX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.28 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 1.64. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 13.62, the price-to-book (PB) ratio at 2.77.

The quick ratio of Jaguar Health Inc. for the three months ended June 29 was 3.20, and the current ratio was 3.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.76 and a total debt to equity ratio of 0.80 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 59.60% against a 5-year average of 55.9%. Jaguar Health Inc.’s EBITDA margin for the year ending June 29 is -259.64%. Its gross profit as reported stood at $6.11 million compared to revenue of $9.38 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Jaguar Health Inc.’s return on assets was -84.20%, compared to -113.3% over the last five years. In the past year, the return on investment has been -85.40%, and the 5-year average is -172.7%. Meanwhile, the return on equity (ROE) for the past 12 months has been -220.40% and the 5-year average holds at -603.0%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

The analyst consensus anticipated Jaguar Health Inc.’s latest quarter earnings to come in at -$0.12 per share, but it turned out to be -$0.3, a -150.00% surprise. For the quarter, EBITDA amounted to -$9.92 million. Shareholders own equity worth $46.48 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Jaguar Health Inc. (JAGX) price momentum. RSI 9-day as of the close on 06 October was 34.36%, suggesting the stock is Neutral, with historical volatility in this time frame at 65.17%.

As of today, JAGX’s price is $2.0838 -9.29% or -$0.2108 from its 5-day moving average. JAGX is currently trading -22.88% lower than its 20-day SMA and -44.20% lower than its 100-day SMA. However, the stock’s current price level is -54.84% below the SMA50 and +101.23% above the SMA200.

The stochastic %K and %D were 14.23% and 12.80%, respectively, and the average true range (ATR) was 0.1773. With the 14-day stochastic at 24.60% and the average true range at 0.1944, the RSI (14) stands at 32.17%. The stock has reached -0.1224 on the 9-day MACD Oscillator while the 14-day reading was at -0.1669.

Analyst Ratings

Cantor Fitzgerald launched coverage on Jaguar Health Inc. (NASDAQ: JAGX) in its analyst report released on July 07, 2021. The firm assigned the stock a an Overweight rating.The consensus rating for Jaguar Health Inc. (JAGX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JAGX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.

What is JAGX’s price target for the next 12 months?

Analysts predict a range of price targets between $13.00 and $15.00, with a median target of $14.00. Taking a look at these predictions, the average price target given by analysts for Jaguar Health Inc. (JAGX) stock is $14.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam